| Autor: |
Arman I; Laboratory of Molecular Immunology and Immunotherapy, Faculty of Biology, Technion-Israel Institute of Haifa, Haifa 320003, Israel., Haus-Cohen M; Laboratory of Molecular Immunology and Immunotherapy, Faculty of Biology, Technion-Israel Institute of Haifa, Haifa 320003, Israel., Reiter Y; Laboratory of Molecular Immunology and Immunotherapy, Faculty of Biology, Technion-Israel Institute of Haifa, Haifa 320003, Israel. |
| Jazyk: |
angličtina |
| Zdroj: |
Cells [Cells] 2022 Dec 21; Vol. 12 (1). Date of Electronic Publication: 2022 Dec 21. |
| DOI: |
10.3390/cells12010027 |
| Abstrakt: |
The impressive clinical success of cancer immunotherapy has motivated the continued search for new targets that may serve to guide potent effector functions in an attempt to efficiently kill malignant cells. The intracellular proteome is an interesting source for such new targets, such as neo-antigens and others, with growing interest in their application for cell-based immunotherapies. These intracellular-derived targets are peptides presented by MHC class I molecules on the cell surface of malignant cells. These disease-specific class I HLA-peptide complexes can be targeted by specific TCRs or by antibodies that mimic TCR-specificity, termed TCR-like (TCRL) antibodies. Adoptive cell transfer of TCR engineered T cells and T-cell-receptor-like based CAR-T cells, targeted against a peptide-MHC of interest, are currently tested as cancer therapeutic agents in pre-clinical and clinical trials, along with soluble TCR- and TCRL-based agents, such as immunotoxins and bi-specific T cell engagers. Targeting the intracellular proteome using TCRL- and TCR-based molecules shows promising results in cancer immunotherapy, as exemplified by the success of the anti-gp100/HLA-A2 TCR-based T cell engager, recently approved by the FDA for the treatment of unresectable or metastatic uveal melanoma. This review is focused on the selection and isolation processes of TCR- and TCRL-based targeting moieties, with a spotlight on pre-clinical and clinical studies, examining peptide-MHC targeting agents in cancer immunotherapy. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
